Welcome to our dedicated page for Neuraxis SEC filings (Ticker: NRXS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
NeurAxis, Inc. filings document the regulatory, financial, governance, and capital-structure disclosures of a medical technology company built around PENFS neuromodulation. Its 8-K reports cover preliminary operating results, FDA 510(k) clearance for PENFS indications, at-the-market common stock offering arrangements under a Form S-3 registration statement, related prospectus supplements and legal opinions, and material agreements involving licensed neuromodulation assets.
NeurAxis proxy materials disclose annual meeting matters, director elections, auditor ratification, equity incentive plan amendments, an employee stock purchase plan, and voting rights involving common stock and Series B Preferred Stock. The filing record also documents corporate governance, stock-based compensation plans, material contract changes, and risk-bearing financing mechanisms tied to its commercialization strategy.
Neuraxis, INC Chief Executive Officer Brian Allen Carrico purchased additional company stock in the open market. On April 1, 2026, he bought 8,060 shares of Neuraxis common stock at $1.96 per share.
After this transaction, Carrico directly owns 348,178 shares of Neuraxis common stock, modestly increasing his personal stake in the company.
Neuraxis, Inc. develops drug-free neuromodulation devices for chronic gastrointestinal and pain conditions, focusing initially on pediatric patients with disorders of gut-brain interaction. Its lead product, IB-Stim, is an FDA Class II PENFS device for functional abdominal pain associated with irritable bowel syndrome and functional dyspepsia in patients 8 years and older.
The company has also launched RED (Rectal Expulsion Device) for office-based assessment of pelvic floor dysfunction and rectal hypersensitivity in adults, and has additional PENFS indications in randomized trials, including post-concussion syndrome, cyclic vomiting syndrome, post-operative opioid-sparing pain control and fibromyalgia.
IB-Stim is priced at $1,195 per device, or $4,780 per standard four-device treatment course. Key access milestones include a Category I CPT code 64567 effective January 1, 2026, inclusion of PENFS as the only FDA-cleared treatment in NASPGHAN pediatric functional abdominal pain guidelines, and a Federal Supply Schedule contract for IB-Stim. As of March 12, 2026, Neuraxis had 11,187,639 common shares outstanding, and non-affiliate equity was valued at approximately $20.4 million at its most recent second-quarter end.
Neuraxis, Inc. reported that executive Adrian Miranda, its CMO and SVP of Science & Technology, acquired 47,569 restricted stock units (RSUs) on January 22, 2026. These equity awards were granted as compensation under the Neuraxis, Inc. 2022 Omnibus Securities and Incentive Plan.
The RSUs vest in three equal annual installments over a three-year period, aligning Miranda’s compensation with longer-term company performance. After this grant, Miranda directly holds 47,569 derivative securities linked to Neuraxis common stock.
Watkins Bradley Mitchell reported acquisition or exercise transactions in this Form 4 filing.
Neuraxis, Inc. director Watkins Bradley Mitchell received a grant of 21,598 shares of common stock on January 22, 2026, as compensation for serving as an independent director. The shares were valued at $4.63 each, bringing his directly held stake to 46,335 shares after the award.
Neuraxis, INC director granted shares as equity compensation. Director Jane Elizabeth Keyser acquired 21,598 shares of Neuraxis common stock on January 22, 2026 at a stated price of $4.63 per share through a grant, not an open-market purchase.
After this award, she directly owns 46,335 common shares. According to the disclosure, these shares were issued as compensation for her services as an independent director, meaning this is a non-cash equity grant rather than a cash investment into the company’s stock.
Neuraxis, Inc. reported that its Chief Financial Officer, Timothy Robert Henrichs, acquired 75,231 restricted stock units (RSUs) on common stock as an equity award. The RSUs were granted at a reference value of $4.63 per share and will vest in three equal annual installments over a three-year period, aligning the CFO’s compensation with long-term shareholder interests. All 75,231 RSUs are held as direct ownership following this grant.
Carrico Brian Allen reported acquisition or exercise transactions in this Form 4 filing.
Neuraxis, Inc. Chief Executive Officer Brian Allen Carrico reported an award of 94,173 restricted stock units (RSUs) on common stock. The RSUs were granted as compensation under the Neuraxis, Inc. 2022 Omnibus Securities and Incentive Plan, as amended.
The RSUs vest in three equal annual installments over a three-year period, meaning portions of the award will be delivered over time if service-based conditions are met. This is an equity-based compensation grant, not an open-market share purchase or sale.
Neuraxis, Inc. 10% owner Brian P. Hannasch reported open-market purchases of the company’s common stock. He bought 40,000 shares on February 11, 2026 at a weighted average price of $4.65 per share and another 40,000 shares on February 12, 2026 at a weighted average price of $4.92 per share. Following these transactions, he directly beneficially owned 1,211,522 shares of Neuraxis common stock.
Neuraxis, Inc. received an updated Schedule 13G/A showing that investment entities linked to Michael Bigger hold a meaningful minority stake in its common stock. As of February 3, 2026, Bigger Capital Fund, LP beneficially owned 801,400 shares of common stock, or about 7.52% of the class.
District 2 Capital Fund LP beneficially owned 175,560 shares, or about 1.65%. Through his roles in these entities, Michael Bigger may be deemed to beneficially own a total of 976,960 shares, or roughly 9.17% of Neuraxis’ outstanding common stock, based on 10,652,812 shares outstanding as of November 7, 2025.
The reporting group certifies that the securities were not acquired and are not held for the purpose of changing or influencing control of Neuraxis, indicating a passive investment stance under the Schedule 13G framework.
Neuraxis, Inc. director receives stock compensation. On 01/22/2026, the director was awarded 21,598 common shares at $4.63 per share as compensation for serving as an independent director. After this grant, the director beneficially owns 307,736 shares, including 286,138 shares held by Rosalind Master Fund L.P.